Summary

ADC Contract Manufacturing Market (6th Edition): Industry Trends and Global Forecasts, till 2035 – Distribution by Stage of Development (Phase I, Phase II, Phase III and Commercial), Process Component (Antibody, HPAPI / Cytotoxic Payload, Conjugation / Linker and Fill / Finish), Target Indication (Solid Tumors, Hematological Tumors and Others), Antibody Generation (Second, Third, Fourth and Next), Antibody Origin (Humanized, Chimeric, Murine and Others), Antibody Isotype (IgG1, IgG4 and Others), Type of Payload (Auristatin, Camptothecin, DNA Topoisomerase I Inhibitor, Maytansinoid and Others), Type of Linker (Maleimide, SMCC, Tetrapeptide-based linker, Valine-citrulline and Others), and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)
Report Link: https://www.rootsanalysis.com/reports/adc-contract-manufacturing-market/218.html
The ADC Contract Manufacturing Market is expected to reach USD 1.79 billion anticipated to grow at a CAGR of 13% during the forecast period 2024-2035.

In recent years, antibody drug conjugates (ADCs) have emerged as a potent therapeutic strategy for treating a wide range of cancers, including solid tumors and hematological malignancies. These advanced compounds consist of an antibody chemically linked to biologically active cytotoxic agents, offering enhanced stability, precision targeting, tumor selectivity, and favorable pharmacokinetic properties. These qualities have catalyzed extensive research and development endeavors aimed at advancing ADC therapies towards commercialization. Currently, the ADC pipeline encompasses over 260 candidates undergoing clinical assessment, alongside 23 ADC therapeutic programs already authorized by regulatory agencies. The potential of such treatments to precisely target tumor cells while minimizing off-target effects has fueled their success and widespread adoption in the healthcare domain.

However, the manufacturing process for ADCs is notably intricate, fraught with various challenges such as drug/linker side reactions, exposure to toxicity, contamination risks, and difficulties in scaling up production. Moreover, it requires substantial expertise and state-of-the-art technologies, resulting in significant costs. Consequently, ADC developers frequently choose to outsource manufacturing operations to specialized ADC contract manufacturers. By capitalizing on the knowledge, capabilities, and production facilities of these contract manufacturing organizations (CMOs), ADC therapy developers aim to streamline manufacturing processes and reduce expenses. Importantly, CMOs engaged in ADC contract manufacturing are actively evolving into comprehensive solution providers, addressing issues related to technology transfer and scaling up production. With the increasing demand for ADCs and the growing trend of outsourcing among drug developers, the ADC contract manufacturing market is poised for substantial growth in the coming years.

Research Coverage:
A comprehensive examination of the fundamental elements comprising ADC therapeutics, the manufacturing challenges inherent in such therapies, and insights into the burgeoning trend of contract manufacturing within this sector of the biopharmaceutical industry.
Conducting a thorough examination of the expansive market terrain for ADC contract manufacturers entails assessing several key factors. These factors encompass the founding year, company size indicated by workforce size, headquarters location, and the spectrum of ADC manufacturing services provided, which includes antibody manufacturing, HPAPI and payload synthesis, linker manufacturing, conjugation, and fill/finish services. Moreover, attention is directed towards the array of supplementary services offered, such as proof-of-concept studies, process development and scale-up, and analytical development. The operational scope, classified into preclinical, clinical, and commercial phases, is also of paramount importance. Furthermore, the geographical distribution of manufacturing facilities significantly influences the overall landscape of ADC contract manufacturers.
A thorough evaluation of the competitive landscape among ADC contract manufacturers involves analyzing their strengths across manufacturing, service, and supplier domains. Manufacturing strength is gauged by factors such as the scale of operation and the number of ADC manufacturing facilities. Service strength encompasses the breadth of ADC services offered, the variety of additional services available, and the geographic distribution of manufacturing facilities. Supplier strength is assessed based on employee count and years of experience within the industry.
Detailed profiles of ADC contract manufacturers, selected through a rigorous competitiveness analysis, offer concise snapshots of each company. These profiles encompass an overview of the company, financial details where accessible, a rundown of their manufacturing services tailored to antibody drug conjugates, the geographical placement of production facilities, and an illuminating recent development alongside future prospect.
Comprehensive analysis of the various expansion initiatives undertaken by ADC contract manufacturers, during the period 2019-2023, along with information on several relevant parameters, such as year of expansion, type of expansion, purpose of expansion (manufacturing, analytical / development and fill / finish), scale of operation (preclinical, clinical and commercial), location of expanded facility, type of facility and most active players (based on number of expansion initiatives).
Insightful assessment of the recent partnerships inked between various ADC contract manufacturers, since 2019, based on several parameters, such as year of partnership, type of partnership (acquisitions, joint ventures, licensing agreements, manufacturing agreements, mergers, product development agreements, product development and manufacturing agreements, research agreements, technology integration agreements and others), purpose of agreement, scale of operation and most active players (in terms of number of partnerships). This section also highlights the regional distribution of partnership activity in this market.
A qualitative examination illuminates the multifaceted considerations that ADC developers must ponder when deliberating whether to conduct in-house manufacturing or outsource operations to contract service providers.
An in-depth exploration of the manufacturing process for ADCs entails a detailed examination of each step, including antibody manufacturing, payload manufacturing, linker manufacturing, conjugation, and fill/finish. Additionally, insights into the associated cost requirements for each stage are provided.
An estimation of the collective ADC manufacturing/bioconjugation capacity, measured in kilograms, among ADC contract manufacturers is derived from data sourced from diverse stakeholders in the public domain. This analysis delineates the global capacity distribution across different company sizes (small, mid-sized, and large), prominent geographical regions (North America, Europe, and Asia-Pacific), and key players identified by their highest bioconjugation capacity.
An overview the present market scenario for ADCs, coupled with an intricate examination of the ADCs pipeline, focusing on numerous key parameters, including development status, targeted disease indications, therapeutic categories, treatment sequence, dosing intervals, therapy types, antigen targets, antibody types, cytotoxic payloads, and linker types.
Elaborate analysis of completed and ongoing clinical studies of various antibody drug conjugates, based on several relevant parameters, such as trial registration year, trial status, trial phase, enrolled patient population, type of sponsor / collaborator, target population, study design, most active industry players, and non-industry players (in terms of number of trials) and key geographical regions.
An in-depth analysis of over 140 ADC therapy developers that are likely to partner with ADC contract manufacturers, based on several relevant parameters, such as developer strength (in terms of company size and its experience), pipeline maturity (in terms of number of drugs in pipeline, their stage of development and type of target indication) and manufacturing capabilities.
An informed estimate of the annual commercial and clinical demand for ADC therapeutics (in kilograms) based on, based on relevant parameters, such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.
A detailed regional capability assessment framework comparing the key geographies, based on a number of parameters, including the number of ADC contract manufacturers, number of ADC manufacturing facilities, number of facility expansions, installed ADC bioconjugation capacity, number of registered clinical trials and demand for ADCs in that particular geographical region.
A detailed assessment of the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments, plotted on a 2×2 matrix.
A detailed ADC contract manufacturing market forecast analysis in order to estimate the existing market size and future opportunity for ADC contract manufacturers over the next 12 years. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market size during the forecast period 2024-2035.
Comprehensive projections of the current and future opportunity within the ADC contract manufacturing market across different stages of development, such as phase I, phase II, phase III and commercial.
Elaborative projections of the current and future opportunity within antibody drug conjugates contract manufacturing market across different process components, such as antibody, HPAPI / cytotoxic payload, conjugation / linker and fill / finish.
Elaborate projections of the current and future opportunity within the ADC contract manufacturing industry across different target indications, such as solid tumors, hematological tumors and others.
Comprehensive projections of the current and future opportunity within the market across different antibody generations, such as second, third, fourth and next generation.
Detailed projections of the current and future opportunity within the ADC contract manufacturing market across different antibody origins, such as humanized, chimeric, murine and others.
Detailed projections of the current and future opportunity within the antibody drug conjugates contract manufacturing market across different antibody isotypes, such as IgG1, IgG4 and others.
Comprehensive projections of the current and future opportunity within the ADC contract manufacturing market across different types of payloads, such as auristatin, camptothecin, DNA topoisomerase I inhibitor, maytansinoid and others.
Elaborate projections of the current and future opportunity within the market across different types of linkers, such as Maleimide, SMCC, tetrapeptide-based linker, valine-citrulline and others.
Detailed projections of the current and future opportunity within the ADC contract manufacturing industry across key geographical regions, including North America, Europe, Asia-Pacific and rest of the world.
Detailed projections of the current and future opportunity within the commercial ADC contract manufacturing market, based on several relevant parameters such as type of component, target indications, type of generation, type of antibody origin, type of antibody isotype, type of payload, type of linker and key geographical regions.
Detailed projections of the current and future opportunity within the clinical ADC contract manufacturing market, based on several relevant parameters such as phase of development, type of component, target indications, type of antibody origin, type of antibody isotype, type of payload, type of linker and key geographical regions.
An in-depth analysis of the factors that can impact the growth of ADC contract manufacturing market. It also features identification of key drivers, potential restraints, emerging opportunities, and existing challenges.
Key Benefits of Buying this Report
The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
The report provides stakeholders with a pulse on the ADC Contract Manufacturing Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
Leading Market Companies
AbbVie Contract Manufacturing
Abzena
CARBOGEN AMCIS
Catalent Pharma Solutions
Cerbios-Pharma
Formosa Laboratories
GBI
Lonza
MabPlex
Millipore Sigma
Piramal Pharma Solutions
Sterling Pharma Solutions
WuXi Biologics

ページTOPに戻る

Table of Contents

1. PREFACE
1.1. ADC Contract Manufacturers: Market Overview
1.2. Market Share Insights
1.3. Market Segmentation Overview
1.4. Key Market Insights
1.5. Report Coverage
1.6. Key Questions Answered
1.7. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. Chapter Overview
5.2. Key Components of ADCs
5.2.1. Antibody
5.2.2. Cytotoxin (Payloads)
5.2.3. Linker

5.3. ADC Manufacturing
5.3.1. Key Steps
5.3.2. Technical Challenges
5.3.3. Need for Outsourcing

5.4. Challenges Associated with Supply Chain and Method Transfer
5.4.1. Growing Demand for One-Stop Shops and Integrated Service Providers

5.5. Selecting a CMO Partner
5.6. Future Perspective

6. ADC CONTRACT MANUFACTURERS: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. ADC Contract Manufacturers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Type of ADC Manufacturing Service Offered
6.2.5. Analysis by Type of Additional Service Offered
6.2.6. Analysis by Scale of Operation
6.2.7. Analysis by Location of Manufacturing Facilities

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. MabPlex
7.2.1. Company Overview
7.2.2. ADC Related Services
7.2.3. Manufacturing Facilities
7.2.4. Recent Developments and Future Outlook

7.3. Lonza
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. ADC Related Services
7.3.4. Manufacturing Facilities
7.3.5. Recent Developments and Future Outlook

7.4. Abzena
7.4.1. Company Overview
7.4.2. ADC Related Services
7.4.3. Manufacturing Facilities
7.4.4. Recent Developments and Future Outlook

7.5. GBI
7.5.1. Company Overview
7.5.2. ADC Related Services
7.5.3. Manufacturing Facilities
7.5.4. Recent Developments and Future Outlook

7.6. CARBOGEN AMCIS
7.6.1. Company Overview
7.6.2. ADC Related Services
7.6.3. Manufacturing Facilities
7.6.4. Recent Developments and Future Outlook

7.7. Millipore Sigma
7.7.1. Company Overview
7.7.2. ADC Related Offerings
7.7.3. Manufacturing Facilities
7.7.4. Recent Developments and Future Outlook

7.8. WuXi Biologics
7.8.1. Company Overview
7.8.2. Financial Information
7.8.3. ADC Related Services
7.8.4. Manufacturing Facilities
7.8.5. Recent Developments and Future Outlook

7.9. Catalent Pharma Solutions
7.9.1. Company Overview
7.9.2. Financial Information
7.9.3. ADC Related Services
7.9.4. Manufacturing Facilities
7.9.5. Recent Developments and Future Outlook

7.10. Cerbios-Pharma
7.10.1. Company Overview
7.10.2. ADC Related Services
7.10.3. Manufacturing Facilities
7.10.4. Recent Developments and Future Outlook

7.11. Formosa Laboratories
7.11.1. Company Overview
7.11.2. ADC Related Services
7.11.3. Manufacturing Facilities
7.11.4. Recent Developments and Future Outlook

7.12. Sterling Pharma Solutions
7.12.1. Company Overview
7.12.2. ADC Related Services
7.12.3. Manufacturing Facilities
7.12.4. Recent Developments and Future Outlook

7.13. Piramal Pharma Solutions
7.13.1. Company Overview
7.13.2. ADC Related Services
7.13.3. Manufacturing Facilities
7.13.4. Recent Developments and Future Outlook

7.14. AbbVie Contract Manufacturing
7.14.1. Company Overview
7.14.2. ADC Related Services
7.14.3. Manufacturing Facilities
7.14.4. Recent Developments and Future Outlook

8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. ADC Contract Manufacturers: Company Competitiveness Analysis
8.4.1. ADC Contract Manufacturers based in North America (Peer Group I)
8.4.2. ADC Contract Manufacturers based in Europe (Peer Group II)
8.4.3. ADC Contract Manufacturers based in Asia-Pacific (Peer Group III)

8.5. Capability Benchmarking of Top ADC Contract Manufacturers

9. ADC CONTRACT MANUFACTURERS: RECENT EXPANSIONS
9.1. Chapter Overview
9.2. ADC Contract Manufacturers: Recent Expansions
9.2.1. Analysis by Year of Expansion
9.2.2. Analysis by Type of Expansion
9.2.3. Analysis by Purpose of Expansion
9.2.4. Analysis by Scale of Operation
9.2.5. Analysis by Location of Expanded Facility
9.2.6. Most Active Players: Analysis by Number of Expansions

10. ADC CONTRACT MANUFACTURERS: PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. ADC Contract Manufacturers: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Purpose of Partnership
10.3.4. Analysis by Scale of Operation
10.3.5. Most Active Players: Analysis by Number of Partnerships

10.3.6. Analysis by Geography
10.3.6.1. Intercontinental and Intracontinental Agreements
10.3.6.2. Local and International Agreements

11. MAKE VERSUS BUY DECISION MAKING
11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.2.1. Scenario 1
11.2.2. Scenario 2
11.2.3. Scenario 3
11.2.4. Scenario 4

11.3. Concluding Remarks

12. VALUE CHAIN ANALYSIS
12.1. Chapter Overview
12.2. ADC Development Value Chain
12.3. Cost Distribution across the Value Chain
12.3.1. Cost Associated with Antibody Manufacturing
12.3.2. Cost Associated with Payload and Linker Manufacturing
12.3.3. Cost Associated with Conjugation
12.3.4. Cost Associated with Fill / Finish

13. ADC MANUFACTURING: CAPACITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. ADC Manufacturing: Global Installed Capacity
13.3.1. Analysis by Company Size
13.3.2. Analysis by Location of Headquarters

13.3.3. Analysis by Location of Manufacturing Facilities
13.3.3.1 Analysis by Region
13.3.3.2. Analysis by Country

13.3.4. Analysis by Key Players

14. ADC THERAPEUTICS: MARKET OVERVIEW
14.1. Chapter Overview
14.2. Antibody Drug Conjugates: Therapies Pipeline
14.2.1. Analysis by Status of Development
14.2.2. Analysis by Target Disease Indication
14.2.3. Analysis by Therapeutic Area
14.2.4. Analysis by Line of Treatment
14.2.5. Analysis by Dosing Frequency
14.2.6. Analysis by Type of Therapy
14.2.7. Analysis by Target Antigen
14.2.8. Analysis by Antibody Isotype
14.2.9. Analysis by Payload / Cytotoxin / Warhead
14.2.10. Analysis by Type of Payload
14.2.11. Analysis by Linker
14.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)

14.3. Antibody Drug Conjugates: Therapies to Watch
14.4. Concluding Remarks

15. CLINICAL TRIAL ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Antibody Drug Conjugates: Clinical Trial Analysis
15.3.1. Analysis by Trial Registration Year
15.3.2. Analysis by Trial Status
15.3.3. Analysis of Enrolled Patient Population by Trial Status
15.3.4. Analysis by Trial Registration Year and Trial Status
15.3.5. Analysis of Enrolled Patient Population by Trial Registration Year
15.3.6. Analysis by Trial Phase
15.3.7. Analysis of Enrolled Patient Population by Trial Phase
15.3.8. Analysis by Type of Sponsor / Collaborator
15.3.9. Analysis by Target Population
15.3.10. Analysis by Study Design
15.3.11. Most Active Industry Players: Analysis by Number of Trials
15.3.12. Most Active Non-Industry Players: Analysis by Number of Trials
15.3.13. Analysis of Clinical Trials by Geography
15.3.14. Analysis of Enrolled Patient Population by Geography

16. LIKELY PARTNER ANALYSIS
16.1. Chapter Overview
16.2. Scoring Criteria and Key Assumptions
16.3. Scope and Methodology

16.4. Potential Strategic Partners based in North America
16.4.1. Most Likely Partners
16.4.2. Likely Partners
16.4.3. Least Likely Partners

16.5. Potential Strategic Partners based in Europe
16.5.1. Most Likely Partners
16.5.2. Likely Partners
16.5.3. Least Likely Partners

16.6. Potential Strategic Partners based in Asia-Pacific and Rest of the World
16.6.1. Most Likely Partners
16.6.2. Likely Partners
16.6.3. Least Likely Partners

17. ADC THERAPEUTICS: DEMAND ANALYSIS
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. ADC Therapeutics: Global Annual Demand
17.3.1. ADC Therapeutics: Annual Commercial Demand
17.3.1.1. Analysis by Target Indication
17.3.1.2. Analysis by Antibody Origin
17.3.1.3. Analysis by Antibody Isotype
17.3.1.4. Analysis by Type of Payload
17.3.1.5. Analysis by Type of Linker
17.3.1.6 Analysis by Key Geographical Regions

17.3.2. ADC Therapeutics: Annual Clinical Demand
17.3.2.1. Analysis by Phase of Development
17.3.2.2. Analysis by Target Indication
17.3.2.3. Analysis by Antibody Origin
17.3.2.4. Analysis by Antibody Isotype
17.3.2.5. Analysis by Type of Payload
17.3.2.6. Analysis by Type of Linker
17.3.2.7. Analysis by Key Geographical Regions

18. REGIONAL CAPABILITY ANALYSIS
18.1. Chapter Overview
18.2. Assumptions and Key Parameters
18.3. ADC Contract Manufacturing Capabilities in North America
18.4. ADC Contract Manufacturing Capabilities in Europe
18.5. ADC Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World

19. ATTRACTIVENESS COMPETETIVENESS MATRIX
19.1. Chapter Overview
19.2. AC Matrix: Overview
19.2.1. Strong Business Segments
19.2.2. Average Business Segments
19.2.3. Weak Business Segments

19.3. AC Matrix: Analytical Methodology

19.4. AC Matrix: Overall ADC Contract Manufacturing Market Scenario
19.4.1. AC Matrix: ADC Contract Manufacturing Scenario for Type of ADC Manufacturing Service Offered
19.4.2. AC Matrix: ADC Contract Manufacturing Scenario for Key Geographical Regions

20. ADC CONTRACT MANUFACTURING MARKET
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Global ADC Therapeutics Market, Historical Trends and Forecasted Estimates, till 2035
20.4. Global ADC Contract Manufacturing Market, Historical Trends and Forecasted Estimates, till 2035
20.4.1. Scenario Analysis

20.5. Key Market Segmentations

21. ADC CONTRACT MANUFACTURING MARKET, BY STAGE OF DEVELOPMENT
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. ADC Contract Manufacturing Market: Distribution by Stage of Development, 2023, 2028 and 2035
21.3.1. Phase I: Forecasted Estimates, till 2035
21.3.2. Phase II: Forecasted Estimates, till 2035
21.3.3. Phase III: Forecasted Estimates, till 2035
21.3.4. Commercial: Forecasted Estimates, till 2035

21.4. Data Triangulation and Validation

22. ADC CONTRACT MANUFACTURING MARKET, BY PROCESS COMPONENT
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. ADC Contract Manufacturing Market: Distribution by Process Component, 2023, 2028 and 2035
22.3.1. Antibody: Forecasted Estimates, till 2035
22.3.2. HPAPI / Cytotoxic Payload: Forecasted Estimates, till 2035
22.3.3. Conjugation / Linker: Forecasted Estimates, till 2035
22.3.4. Fill / Finish: Forecasted Estimates, till 2035

22.4. Data Triangulation and Validation

23. ADC CONTRACT MANUFACTURING MARKET, BY TARGET INDICATION
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. ADC Contract Manufacturing Market: Distribution by Target Indication, 2023, 2028 and 2035
23.3.1. Solid Tumors: Forecasted Estimates, till 2035
23.3.2. Hematological Tumors: Forecasted Estimates, till 2035
23.3.3. Others: Forecasted Estimates, till 2035

23.4. Data Triangulation and Validation

24. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY GENERATION
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. ADC Contract Manufacturing Market: Distribution by Antibody Generation, 2023, 2028 and 2035
24.3.1. Second Generation: Forecasted Estimates, till 2035
24.3.2. Third Generation: Forecasted Estimates, till 2035
24.3.3. Fourth Generation: Forecasted Estimates, till 2035
24.3.4. Next Generation: Forecasted Estimates, till 2035

24.4. Data Triangulation and Validation

25. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY ORIGIN
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. ADC Contract Manufacturing Market: Distribution by Antibody Origin, 2023, 2028 and 2035
25.3.1. Human Origin: Forecasted Estimates, till 2035
25.3.2. Chimeric Origin: Forecasted Estimates, till 2035
25.3.3. Murine Origin: Forecasted Estimates, till 2035
25.3.4. Others: Forecasted Estimates, till 2035

25.4. Data Triangulation and Validation

26. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY ISOTYPE
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. ADC Contract Manufacturing Market: Distribution by Antibody Isotype, 2023, 2029 and 2035
26.3.1. IgG1: Forecasted Estimates, till 2035
26.3.2. IgG4: Forecasted Estimates, till 2035
26.3.3. Others: Forecasted Estimates, till 2035

26.4. Data Triangulation and Validation

27. ADC CONTRACT MANUFACTURING MARKET, BY TYPE OF PAYLOAD
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. ADC Contract Manufacturing Market: Distribution by Type of Payload, 2023, 2029 and 2035
27.3.1.Camptothecin: Forecasted Estimates, till 2035
27.3.2. Maytansinoid: Forecasted Estimates, till 2035
27.3.3. Auristatin: Forecasted Estimates, till 2035
27.3.4. DNA topoisomerase I inhibitor: Forecasted Estimates, till 2035
27.3.5. Others: Forecasted Estimates, till 2035

27.4. Data Triangulation and Validation

28. ADC CONTRACT MANUFACTURING MARKET, BY TYPE OF LINKER
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. ADC Contract Manufacturing Market: Distribution by Type of Linker, 2023, 2029 and 2035
28.3.1. Maleimide: Forecasted Estimates, till 2035
28.3.2. SMCC: Forecasted Estimates, till 2035
28.3.3. Tetrapeptide-based linker: Forecasted Estimates, till 2035
28.3.4. Valine-citrulline: Forecasted Estimates, till 2035
28.3.5. Others: Forecasted Estimates, till 2035

28.4. Data Triangulation and Validation

29. ADC CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS
29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, 2023, 2029 and 2035
29.3.1. North America: Forecasted Estimates, till 2035
29.3.2. Europe: Forecasted Estimates, till 2035
29.3.3. Asia-Pacific and Rest of the World: Forecasted Estimates, till 2035

29.4. Data Triangulation and Validation

30. COMMERCIAL ADC CONTRACT MANUFACTURING MARKET
30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Commercial ADC Contract Manufacturing Market, Forecasted Estimates, till 2035
30.3.1. Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035
30.3.2. Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035
30.3.3. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Generation, Forecasted Estimates, till 2035
30.3.4. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035
30.3.5. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035
30.3.6. Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035
30.3.7. Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035
30.3.8. Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035

30.4. Data Triangulation and Validation

31. CLINICAL ADC CONTRACT MANUFACTURING MARKET
31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Clinical ADC Contract Manufacturing Market, Forecasted Estimates, till 2035
31.3.1. Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates, till 2035
31.3.2. Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035
31.3.3. Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035
31.3.4. Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035
31.3.5. Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035
31.3.6. Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035
31.3.7. Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035
31.3.8. Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035

31.4. Data Triangulation and Validation

32. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
32.1. Chapter Overview
32.2. Market Drivers
32.3. Market Restraints
32.4. Market Opportunities
32.5. Market Challenges
32.6. Conclusion

33. CONCLUDING REMARKS

34. INTERVIEW TRANSCRIPTS
34.1. Chapter Overview
34.2. Company A
34.2.1. Company Snapshot
34.2.2. Interview Transcript: Chief Executive Officer and Technical Business Development Manager

34.3. Company B
34.3.1. Company Snapshot
34.3.2. Interview Transcript: Chief Executive Officer and Founder

34.4. Company C
34.4.1. Company Snapshot
34.4.2. Interview Transcript: Former Chief Executive Officer

34.5. Company D
34.5.1. Company Snapshot
34.5.2. Interview Transcript: Chief Executive Officer and Co-Founder

34.6. Company E
34.6.1. Company Snapshot
34.6.2. Interview Transcript: Chief Commercial Officer

34.7. Company F
34.7.1. Company Snapshot
34.7.2. Interview Transcript: Chief Business Officer

34.8. Company G
34.8.1. Company Snapshot
34.8.2. Interview Transcript: Executive Director and Chief Innovation Officer

34.9. Company H
34.9.1. Company Snapshot
34.9.2. Interview Transcript: Director, Business Development

34.10. Company I
34.10.1. Company Snapshot
34.10.2. Interview Transcript: Former Director of CDMO

34.11. Company J
34.11.1. Company Snapshot
34.11.2. Interview Transcript: Director Corporate Development

34.12. Company K
34.12.1. Company Snapshot
34.12.2. Interview Transcript: Business Development Manager

34.13. Company L
34.13.1. Company Snapshot
34.13.2. Interview Transcript: Director, Business Development and Former Group Product Manager

34.14. Company M
34.14.1. Company Snapshot
34.14.2. Interview Transcript: Former Head of Bioconjugates Commercial Development

34.15. Company N
34.15.1. Company Snapshot
34.15.2. Interview Transcript: Former Site Head

34.16. Company O
34.16.1. Company Snapshot
34.16.2. Interview Transcript: Associate General Manager

34.17. Interview Transcript: Director, Business Development, Leading CMO
34.18. Interview Transcript: Chief Executive Officer, Leading CMO

35. APPENDIX I: TABULATED DATA

36. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

ページTOPに戻る

List of Tables/Graphs

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentation
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Market Landscape
Figure 4.2 Executive Summary: Recent Expansions
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Capacity Analysis
Figure 4.5 Executive Summary: Clinical Trial Analysis
Figure 4.6 Executive Summary: Demand Analysis
Figure 4.7 Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1 Key Components of an ADC
Figure 5.2 ADC Manufacturing Steps
Figure 5.3 Key Parameters while Selecting a CMO Partner
Figure 6.1 ADC Contract Manufacturers: Distribution by Year of Establishment
Figure 6.2 ADC Contract Manufacturers: Distribution by Company Size
Figure 6.3 ADC Contract Manufacturers: Distribution by Location of Headquarters(Region)
Figure 6.4 ADC Contract Manufacturers: Distribution by Location of Headquarters(Country)
Figure 6.5 ADC Contract Manufacturers: Distribution by Company Size and Location of Headquarters
Figure 6.6 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered
Figure 6.7 ADC Contract Manufacturers: Distribution by Location of Headquartersand ADC Manufacturing Service Offered
Figure 6.8 ADC Contract Manufacturers: Distribution by Type of Additional Service Offered
Figure 6.9 ADC Contract Manufacturers: Distribution by Scale of Operation
Figure 6.10 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered and Scale of Operation
Figure 6.11 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facilities and Type of ADC Manufacturing Service Offered
Figure 7.1 Lonza: Annual Revenues, FY 2019-H1 FY 2023 (CHF Billion)
Figure 7.2 WuXi Biologics: Annual Revenues, FY 2019-H1 FY 2023 (RMB Billion)
Figure 7.3 Catalent Pharma Solutions: Annual Revenues, FY 2019 - FY 2023 (USD Billion)
Figure 8.1 Company Competitiveness Analysis: ADC Contract Manufacturers based in North America
Figure 8.2 Company Competitiveness Analysis: ADC Contract Manufacturers based in Europe
Figure 8.3 Company Competitiveness Analysis: ADC Contract Manufacturers based in Asia-Pacific
Figure 8.4 Capability Benchmarking: Distribution of Top 9 Players (Wind Rose Representation)
Figure 9.1 Recent Expansions: Cumulative Year-wise Trend, 2013-2023
Figure 9.2 Recent Expansions: Distribution by Type of Expansion
Figure 9.3 Recent Expansions: Distribution by Purpose of Expansion
Figure 9.4 Recent Expansions: Distribution by Year of Expansion and Purpose of Expansion
Figure 9.5 Recent Expansions: Distribution by Scale of Operation
Figure 9.6 Recent Expansions: Distribution by Location of Expanded Facility
Figure 9.7 Recent Expansions: Distribution by Location of Expanded Facility and Scale of Operation
Figure 9.8 Most Active Players: Distribution by Number of Expansions
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2012-2023
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Purpose of Partnership
Figure 10.5 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 10.6 Most Active Players: Distribution by Number of Partnership Instances
Figure 10.7 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Figure 10.8 Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 11.1 Make versus Buy Decision Making Framework
Figure 11.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 12.1 Value Chain Analysis: ADC Development Overview
Figure 12.2 Value Chain Analysis: ADC Contract Manufacturing Overview
Figure 12.3 ADC Therapeutics: Distribution by Cost of Raw Material Required for Clinical Stage Manufacturing
Figure 12.4 Value Chain Analysis: Distribution by Cost
Figure 12.5 Costs Associated with Antibody Manufacturing
Figure 12.6 Costs Associated with Payload and Linker Manufacturing
Figure 12.7 Costs Associated with Conjugation
Figure 12.8 Costs Associated with Fill / Finish
Figure 13.1 Global Installed ADC Manufacturing Capacity: Distribution by Company Size
Figure 13.2 Global Installed ADC Manufacturing Capacity: Distribution by Location of Headquarters
Figure 13.3 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Region)
Figure 13.4 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Country)
Figure 13.5 Global Installed ADC Manufacturing Capacity: Distribution by Key Players
Figure 14.1 Antibody Drug Conjugates: Distribution by Status of Development
Figure 14.2 Antibody Drug Conjugates: Distribution by Target Disease Indication
Figure 14.3 Antibody Drug Conjugates: Distribution by Therapeutic Area
Figure 14.4 Antibody Drug Conjugates: Distribution by Line of Treatment
Figure 14.5 Antibody Drug Conjugates: Distribution by Dosing Frequency
Figure 14.6 Antibody Drug Conjugates: Distribution by Type of Therapy
Figure 14.7 Antibody Drug Conjugates: Distribution by Target Antigen
Figure 14.8 Antibody Drug Conjugates: Distribution by Antibody Isotype
Figure 14.9 Antibody Drug Conjugates: Distribution by Payload / Cytotoxin / Warhead
Figure 14.10 Antibody Drug Conjugates: Distribution by Type of Payload
Figure 14.11 Antibody Drug Conjugates: Distribution by Linker
Figure 14.12 Antibody Drug Conjugates: Distribution by Type of Linker
Figure 15.1 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2016-2023
Figure 15.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 15.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status
Figure 15.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2016-2023
Figure 15.5 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, 2016-2023
Figure 15.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 15.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 15.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 15.9 Clinical Trial Analysis: Distribution by Target Population
Figure 15.10 Clinical Trial Analysis: Distribution by Study Design
Figure 15.11 Most Active Industry Players: Distribution by Number of Trials
Figure 15.12 Most Active Non-Industry Players: Distribution by Number of Trials
Figure 15.13 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 15.14 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 17.1 Global Demand for ADC Therapeutics, 2023-2035 (in kg)
Figure 17.2 Global Demand for ADC Therapeutics: Distribution by Stage of Development, 2023-2035 (in kg)
Figure 17.3 Global Commercial Demand for ADC Therapeutics, 2023-2035 (in kg)
Figure 17.4 Global Commercial Demand for ADC Therapeutics: Distribution by Target Indication, 2023-2035 (in kg)
Figure 17.5 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, 2023-2035 (in kg)
Figure 17.6 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2023-2035 (in kg)
Figure 17.7 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Payload, 2023-2035 (in kg)
Figure 17.8 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Linker, 2023-2035 (in kg)
Figure 17.9 Global Commercial Demand for ADC Therapeutics: Distribution by Geography, 2023-2035 (in kg)
Figure 17.10 Global Clinical Demand for ADC Therapeutics, 2023-2035 (in kg)
Figure 17.11 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, 2023-2035 (in kg)
Figure 17.12 Global Clinical Demand for ADC Therapeutics: Distribution by Target Indication, 2023-2035 (in kg)
Figure 17.13 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, 2022-2035 (in kg)
Figure 17.14 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2023-2035 (in kg)
Figure 17.15 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Payload, 2023-2035 (in kg)
Figure 17.16 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Linker, 2023-2035 (in kg)
Figure 17.17 Global Clinical Demand for ADC Therapeutics: Distribution by Geography, 2023-2035 (in kg)
Figure 18.1 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in North America
Figure 18.2 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in Europe
Figure 18.3 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World
Figure 19.1 AC Matrix: Pictorial Representation
Figure 19.2 AC Matrix: Overall ADC Contract Manufacturing Market Scenario, 2023-2028 and 2029-2035
Figure 19.3 AC Matrix: ADC Contract Manufacturing Scenario for Type of ADC Manufacturing Service Offered
Figure 19.4 AC Matrix: ADC Contract Manufacturing Scenario for Key Geographical Regions
Figure 20.1 Global ADC Contract Manufacturing Market, Historical Trends and Forecasted Estimates, till 2035
Figure 20.2 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Base Scenario (USD Million)
Figure 20.3 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Conservative Scenario (USD Million)
Figure 20.4 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Optimistic Scenario (USD Million)
Figure 21.1 Global ADC Contract Manufacturing Market: Distribution by Stage of Development, 2023, 2028 and 2035 (USD Million)
Figure 21.2 ADC Contract Manufacturing Market for Phase I ADCs, Forecasted Estimates, till 2035 (USD Million)
Figure 21.3 ADC Contract Manufacturing Market for Phase II ADCs, Forecasted Estimates, till 2035 (USD Million)
Figure 21.4 ADC Contract Manufacturing Market for Phase III ADCs, Forecasted Estimates, till 2035 (USD Million)
Figure 21.5 ADC Contract Manufacturing Market for Commercial ADCs, Forecasted Estimates, till 2035 (USD Million)
Figure 22.1 Global ADC Contract Manufacturing Market: Distribution by Process Component, 2023, 2028 and 2035 (USD Million)
Figure 22.2 ADC Contract Manufacturing Market for Antibody, Forecasted Estimates, till 2035 (USD Million)
Figure 22.3 ADC Contract Manufacturing Market for HPAPI / Cytotoxic Payload, Forecasted Estimates, till 2035 (USD Million)
Figure 22.4 ADC Contract Manufacturing Market for Conjugation / Linker, Forecasted Estimates, till 2035 (USD Million)
Figure 22.5 ADC Contract Manufacturing Market for Fill / Finish, Forecasted Estimates, till 2035 (USD Million)
Figure 23.1 Global ADC Contract Manufacturing Market: Distribution by Target Indication, 2023, 2028 and 2035 (USD Million)
Figure 23.2 ADC Contract Manufacturing Market for Solid Tumors, Forecasted Estimates, till 2035 (USD Million)
Figure 23.3 ADC Contract Manufacturing Market for Hematological Tumors, Forecasted Estimates, till 2035 (USD Million)
Figure 23.4 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 24.1 Global ADC Contract Manufacturing Market: Distribution by Antibody Generation, 2023, 2028 and 2035 (USD Million)
Figure 24.2 ADC Contract Manufacturing Market for Second Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 24.3 ADC Contract Manufacturing Market for Third Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 24.4 ADC Contract Manufacturing Market for Fourth Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 24.5 ADC Contract Manufacturing Market for Next Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 25.1 Global ADC Contract Manufacturing Market: Distribution by Antibody Origin, 2023, 2028 and 2035 (USD Million)
Figure 25.2 ADC Contract Manufacturing Market for Humanized Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 25.3 ADC Contract Manufacturing Market for Chimeric Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 25.4 ADC Contract Manufacturing Market for Murine Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 25.5 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 26.1 Global ADC Contract Manufacturing Market: Distribution by Antibody Isotype, 2023, 2028 and 2035 (USD Million)
Figure 26.2 ADC Contract Manufacturing Market for IgG1, Forecasted Estimates, till 2035 (USD Million)
Figure 26.3 ADC Contract Manufacturing Market for IgG4, Forecasted Estimates, till 2035 (USD Million)
Figure 26.4 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 27.1 Global ADC Contract Manufacturing Market: Distribution by Type of Payload, 2023, 2028 and 2035 (USD Million)
Figure 27.2 ADC Contract Manufacturing Market for Camptothecin, Forecasted Estimates, till 2035 (USD Billion)
Figure 27.3 ADC Contract Manufacturing Market for Maytansinoid, Forecasted Estimates, till 2035 (USD Billion)
Figure 27.4 ADC Contract Manufacturing Market for Auristatin, Forecasted Estimates, till 2035 (USD Billion)
Figure 27.5 ADC Contract Manufacturing Market for DNA Topoisomerase I Inhibitor, Forecasted Estimates, till 2035 (USD Billion)
Figure 27.6 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 28.1 Global ADC Contract Manufacturing Market: Distribution by Type of Linker, 2023, 2028 and 2035 (USD Million)
Figure 28.2 ADC Contract Manufacturing Market for Maleimide, Forecasted Estimates, till 2035 (USD Million)
Figure 28.3 ADC Contract Manufacturing Market for SMCC, Forecasted Estimates, till 2035 (USD Million)
Figure 28.4 ADC Contract Manufacturing Market for Tetrapeptide-based linker, Forecasted Estimates, till 2035 (USD Million)
Figure 28.5 ADC Contract Manufacturing Market for Valine-citrulline, Forecasted Estimates, till 2035 (USD Million)
Figure 28.6 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 29.1 Global ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035 (USD Million)
Figure 29.2 ADC Contract Manufacturing Market in North America, Forecasted Estimates, till 2035 (USD Million)
Figure 29.3 ADC Contract Manufacturing Market in Europe, Forecasted Estimates, till 2035 (USD Million)
Figure 29.4 ADC Contract Manufacturing Market in Asia-Pacific and Rest of the World, Forecasted Estimates, till 2035 (USD Million)
Figure 30.1 Commercial ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Million)
Figure 30.2 Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Million)
Figure 30.3 Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Million)
Figure 30.4 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 30.5 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 30.6 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Million)
Figure 30.7 Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Million)
Figure 30.8 Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Million)
Figure 30.9 Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Million)
Figure 31.1 Clinical ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Million)
Figure 31.2 Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates, till 2035 (USD Million)
Figure 31.3 Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Million)
Figure 31.4 Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Million)
Figure 31.5 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 31.6 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Million)
Figure 31.7 Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Million)
Figure 31.8 Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Million)
Figure 31.9 Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Million)
Figure 33.1 Concluding Remarks: Market Landscape
Figure 33.2 Concluding Remarks: Recent Expansions
Figure 33.3 Concluding Remarks: Partnerships and Collaborations
Figure 33.4 Concluding Remarks: Clinical Trial Analysis
Figure 33.5 Concluding Remarks: Likely Partner Analysis
Figure 33.6 Concluding Remarks: Capacity Analysis
Figure 33.7 Concluding Remarks: Demand Analysis
Figure 33.8 Concluding Remarks: Market Sizing and Opportunity Analysis (1/3)
Figure 33.9 Concluding Remarks: Market Sizing and Opportunity Analysis (2/3)
Figure 33.10 Concluding Remarks: Market Sizing and Opportunity Analysis (3/3)